Abstract
This chapter centers on the crucial role that lipid II plays on the bacterial cell wall and its putative role as the Achilles’ heel of pathogenic bacteria. Lipid II is an essential molecule for bacterial survival and biomolecules targeting this compound could interrupt the bacterial cell wall synthesis, hence causing bacterial lysis. We will concentrate here on several lipid II-acting lantibiotics, such as telavancin, vancomycin, and plusbacin. Additionally, human defensins and moenomycins will be also mentioned, as they constitute putative future biomolecules to fight bacterial infections.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Altena K, Guder A, Cramer C, Bierbaum G (2000) Biosynthesis of the lantibiotic mersacidin: organization of a type B lantibiotic gene cluster. Appl Environ Microbiol 66:2565–2571
Ambrose AM (1954) Observations on the acute toxicity of cinnamycin, a polypeptide antibiotic. Antibiot Chemother (Northfield III) 4:1242–12244
Appleyard AN, Choi S, Read DM, Lightfoot A, Boakes S, Hoffmann A, Chopra I, Bierbaum G, Rudd BA, Dawson MJ, Cortes J (2009) Dissecting structural and functional diversity of the lantibiotic mersacidin. Chem Biol 16:490–498
Arai M, Nakayama R, Yoshida K, Takeuchi M, Teramoto S, Torikata A (1977) Pholipomycin, a new member of phosphoglycolipid antibiotics. II. Physico-chemical properties and comparison with other members of this family of antibiotics. J Antibiot (Tokyo) 30:1055–1059
Argüelles Arias A, Ongena M, Devreese B, Terrak M, Joris B, Fickers P (2013) Characterization of amylolysin, a novel lantibiotic from Bacillus amyloliquefaciens GA1. PLoS ONE 8:e83037
Arioli V, Berti M, Silvestri LG (1976) Gardimycin, a new antibiotic from Actinoplanes. III. Biological properties. J Antibiot (Tokyo) 29(5):511–515
Asaduzzaman SM, Nagao J, Iida H, Zendo T, Nakayama J, Sonomoto K (2009) Nukacin ISK-1, a bacteriostatic lantibiotic. Antimicrob Agents Chemother 53:3595–3598
Aso Y, Sashihara T, Nagao J, Kanemasa Y, Koga H, Hashimoto T, Higuchi T, Adachi A, Nomiyama H, Ishizaki A, Nakayama J, Sonomoto K (2004a) Characterization of a gene cluster of Staphylococcus warneri ISK-1 encoding the biosynthesis of and immunity to the lantibiotic, nukacin ISK-1. Biosci Biotechnol Biochem 68:1663–1671
Aso Y, Nagao J, Koga H, Okuda K, Kanemasa Y, Sashihara T, Nakayama J, Sonomoto K (2004b) Heterologous expression and functional analysis of the gene cluster for the biosynthesis of and immunity to the lantibiotic, nukacin ISK-1. J Biosci Bioeng 98:429–436
Aso Y, Koga H, Sashihara T, Nagao J, Kanemasa Y, Nakayama J, Sonomoto K (2005) Description of complete DNA sequence of two plasmids from the nukacin ISK-1 producer, Staphylococcus warneri ISK-1. Plasmid 53:164–178
Barr K, Rick PD (1987) Biosynthesis of Enterobacterial Common Antigen in Escherichia coli. In vitro synthesis of lipid-linked intermediates. J Biol Chem 262:7142–7150
Barr K, Ward S, Meier-Dieter U, Mayer H, Rick PD (1988) Characterization of an Escherichia coli rff mutant defective in transfer of N-acetylmannosaminuronic acid (ManNAcA) from UDP-ManNAcA to a lipid-linked intermediate involved in enterobacterial common antigen synthesis. J Bacteriol 170:228–233
Barr K, Nunes-Edwards P, Rick PD (1989) In vitro synthesis of a lipid-linked trisaccharide involved in synthesis of enterobacterial common antigen. J Bacteriol 171:1326–1332
Benedict RG, Dvonch W, Shotwell OL, Pridham TG, Lindenfelser LA (1952) Cinnomycin, an antibiotic from Streptomyces cinnamoneus nov. sp. Antibiot Chemother 2:591–594
Bevins CL (2006) Paneth cell defensins: key effector molecules of innate immunity. Biochem Soc Trans 34:263–266
Bierbaum G, Sahl HG (2009) Lantibiotics: mode of action, biosynthesis and bioengineering. Curr Pharm Biotechnol 10:2–18
Boakes S, Cortés J, Appleyard AN, Rudd BA, Dawson MJ (2009) Organization of the genes encoding the biosynthesis of actagardine and engineering of a variant generation system. Mol Microbiol 72:1126–1136
Boakes S, Ayala T, Herman M, Appleyard AN, Dawson MJ, Cortés J (2012) Generation of an actagardine A variant library through saturation mutagenesis. Appl Microbiol Biotechnol 95:1509–1517
Böttiger T, Schneider T, Martínez B, Sahl HG, Wiedemann I (2009) Influence of Ca++ ions on the activity of lantibiotics containing a mersacidin-like lipid II binding motif. Appl Environ Microbiol 75:4427–4434
Bouhss A, Al-Dabbagh B, Vincent M, Odaert B, Aumont-Nicaise M, Bressolier P, Desmadril M, Mengin-Lecreulx D, Urdaci MC, Gallay J (2009) Specific interactions of clausin, a new lantibiotic, with lipid precursors of the bacterial cell wall. Biophys J 97:1390–1397
Bressollier P, Brugo MA, Robineau P, Schmitter JM, Sofeir M, Urdaci MC, Verneuil B (2007) Peptide compound with biological activity, its preparation and application. WO 2007113691
Breukink E, de Kruijff B (2006) Lipid II as a target for antibiotics. Nat Rev Drug Discovery 5:321–323
Brogden KA, Ackermann M, McCray PB Jr, Tack BF (2003) Antimicrobial peptides in animals and their role in host defences. Int J Antimicrob Agents 22:465–478
Brötz H, Bierbaum G, Markus A, Molitor E, Sahl HG (1995) Mode of action of the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel mechanism? Antimicrob Agents Chemother 39:714–719
Brötz H, Bierbaum G, Reynolds PE, Sahl HG (1997) The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. Eur J Biochem 246:193–199
Brötz H, Bierbaum G, Leopold K, Reynolds PE, Sahl HG (1998) The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. Antimicrob Agents Chemother 42:154–160
Carroll J, Draper LA, O’Connor PM, Coffey A, Hill C, Ross RP, Cotter PD, O’Mahony J (2010) Comparison of the activities of the lantibiotics nisin and lacticin 3147 against clinically significant mycobacteria. Int J Antimicrob Agents 36:132–136
Castiglione F, Cavaletti L, Losi D, Lazzarini A, Carrano L, Feroggio M, Ciciliato I, Corti E, Candiani G, Marinelli F, Selva E (2007) A novel lantibiotic acting on bacterial cell wall synthesis produced by the uncommon actinomycete Planomonospora sp. Biochemistry 46:5884–5895
Chatterjee S, Chatterjee S, Lad SJ, Phansalkar MS, Rupp RH, Ganguli BN, Fehlhaber HW, Kogler H (1992) Mersacidin, a new antibiotic from Bacillus, fermentation, isolation, purification and chemical characterization. J Antibiot (Tokyo) 45:832–838
Cheng TJ, Wu YT, Yang ST, Lo KH, Chen SK, Chen YH, Huang WI, Yuan CH, Guo CW, Huang LY, Chen KT, Shih HW, Cheng YS, Cheng WC, Wong CH (2010) High-throughput identification of antibacterials against methicillin-resistant Staphylococcus aureus (MRSA) and the transglycosylase. Bioorg Med Chem 18:8512–8529
Christ NA, Bochmann S, Gottstein D, Duchardt-Ferner E, Hellmich UA, Düsterhus S, Kötter P, Güntert P, Entian KD, Wöhnert J (2012) The First structure of a lantibiotic immunity protein, SpaI from Bacillus subtilis, reveals a novel fold. J Biol Chem 287:35286–35298
Coronelli C, Tamoni G, Lancini GC (1976) Gardimycin, a new antibiotic from Actinoplanes. II. Isolation and preliminary characterization. J Antibiot (Tokyo) 29:507–510
Cotter PD, O’Connor PM, Draper LA, Lawton EM, Deegan LH, Hill C, Ross RP (2005) Posttranslational conversion of l-serines to d-alanines is vital for optimal production and activity of the lantibiotic lacticin 3147. Proc Natl Acad Sci USA 102:18584–18589
Cotter PD, Deegan LH, Lawton EM, Draper LA, O’Connor PM, Hill C, Ross RP (2006) Complete alanine scanning of the two-component lantibiotic lacticin 3147: generating a blueprint for rational drug design. Mol Microbiol 62:735–747
Crispie F, Flynn J, Ross RP, Hill C, Meaney WJ (2004) Update on the development of a novel dry cow therapy using a bismuth-based intramammary teat seal in combination with the bacteriocin lacticin 3147. Ir Vet J 57:652–656
Dabard J, Bridonneau C, Phillipe C, Anglade P, Molle D, Nardi M, Ladiré M, Girardin H, Marcille F, Gomez A, Fons M (2001) Ruminococcin A, a new lantibiotic produced by a Ruminococcus gnavus strain isolated from human feces. Appl Environ Microbiol 67:4111–4118
Danese PN, Oliver GR, Barr K, Bowman GD, Rick PD, Silhavy TJ (1998) Accumulation of the enterobacterial common antigen lipid II biosynthetic intermediate stimulates degP transcription in Escherichia coli. J Bacteriol 180:5875–5884
de Leeuw E, Li C, Zeng P, Li C, Diepeveen-de Buin M, Lu WY, Breukink E, Lu W (2010) Functional interaction of human neutrophil peptide-1 with the cell wall precursor lipid II. FEBS Lett 584:1543–1548
Derouaux A, Turk S, Olrichs NK, Gobec S, Breukink E, Amoroso A, Offant J, Bostock J, Mariner K, Chopra I, Vernet T, Zervosen A, Joris B, Frère JM, Nguyen-Distèche M, Terrak M (2011) Small molecule inhibitors of peptidoglycan synthesis targeting the lipid II precursor. Biochem Pharmacol 81:1098–1105
Dobson A, O’Connor PM, Cotter PD, Ross RP, Hill C (2011) Impact of the broad-spectrum antimicrobial peptide, lacticin 3147, on Streptococcus mutans growing in a biofilm and in human saliva. J Appl Microbiol 111:1515–1523
Draper LA, Cotter PD, Hill C, Ross RP (2013) The two peptide lantibiotic lacticin 3147 acts synergistically with polymyxin to inhibit Gram negative bacteria. BMC Microbiol 13:212
Drider D, Rebufatt S (eds) (2011) Prokaryotic Antibacterial Peptides. Springer, Germany
Essig A, Hofmann D, Münch D, Gayathri S, Künzler M, Kallio PT, Sahl HG, Wider G, Schneider T, Aebi M (2014) Copsin, a novel peptide-based fungal antibiotic interfering with the peptidoglycan synthesis. J Biol Chem. pii: jbc.M114.599878
Field D, Molloy EM, Iancu C, Draper LA, O’ Connor PM, Cotter PD, Hill C, Ross RP (2013) Saturation mutagenesis of selected residues of the α-peptide of the lantibiotic lacticin 3147 yields a derivative with enhanced antimicrobial activity. Microb Biotechnol 6:564–575
Fredenhagen A, Fendrich G, Märki F, Märki W, Gruner J, Raschdorf F, Peter HH (1990) Duramycins B and C, two new lanthionine containing antibiotics as inhibitors of phospholipase A2. Structural revision of duramycin and cinnamycin. J Antibiot (Tokyo) 43:1403–1412
Ganguli BN, Chatterjee S, Chatterjee S, Kogler H, Fehlhaber HW, Kiesel N, Blumbach J (1989) Program abstract continued 29th interscience conference on antimicrobial agents and chemotheraphy, Abstract 413
Gardiner GE, Rea MC, O’Riordan B, O’Connor P, Morgan SM, Lawlor PG, Lynch PB, Cronin M, Ross RP, Hill C (2007) Fate of the two-component lantibiotic lacticin 3147 in the gastrointestinal tract. Appl Environ Microbiol 73:7103–7109
Georgalaki M, Papadimitriou K, Anastasiou R, Pot B, Van Driessche G, Devreese B, Tsakalidou E (2013) Macedovicin, the second food-grade lantibiotic produced by Streptococcus macedonicus ACA-DC 198. Food Microbiol 33:124–130
Goldman RC, Baizman ER, Branstrom AA, Longley CB (2000) Differential antibacterial activity of moenomycin analogues on gram-positive bacteria. Bioorg Med Chem Lett 10:2251–2254
Gomez A, Ladiré M, Marcille F, Fons M (2002) Trypsin mediates growth phase-dependent transcriptional regulation of genes involved in biosynthesis of ruminococcin A, a lantibiotic produced by a Ruminococcus gnavus strain from a human intestinal microbiota. J Bacteriol 184:18–28
González B, Arca P, Mayo B, Suárez JE (1994) Detection, purification, and partial characterization of plantaricin C, a bacteriocin produced by a Lactobacillus plantarum strain of dairy origin. Appl Environ Microbiol 60:2158–2163
González B, Glaasker E, Kunji E, Driessen A, Suarez JE, Konings WN (1996) Bactericidal mode of action of plantaricin C. Appl Environ Microbiol 62:2701–2709
Grasemann H, Stehling F, Brunar H, Widmann R, Laliberte TW, Molina L, Döring G, Ratjen F (2007) Inhalation of Moli 1901 in patients with cystic fibrosis. Chest 131:1461–1466
Grinter R, Roszak AW, Cogdell RJ, Milner JJ, Walker D (2012) The crystal structure of the lipid II-degrading bacteriocin syringacin M suggests unexpected evolutionary relationships between colicin M-like bacteriocins. J Biol Chem 287:38876–38888
Gross E, Brown JH (1976) Peptides with α,β-unsaturated and thioether amino acids, duramycin. In: Loffet A (ed) Peptides, Editions de l’Universite de Bruxelles, Brüssel, pp 183–190
Guder A, Schmitter T, Wiedemann I, Sahl HG, Bierbaum G (2002) Role of the single regulator MrsR1 and the two-component system MrsR2/K2 in the regulation of mersacidin production and immunity. Appl Environ Microbiol 68:106–113
Halimi B, Dortu C, Arguelles-Arias A, Thonart P, Joris B, Fickers P (2010) Antilisterial activity on poultry meat of amylolysin a bacteriocin from Bacillus amyloliquefaciens GA1. Probiotics Antimicrob Prot 2:120–125
Halliday J, McKeveney D, Muldoon C, Rajaratnam P, Meutermans W (2006) Targeting the forgotten transglycosylases. Biochem Pharmacol 71:957–967
Hao K, He P, Blom J, Rueckert C, Mao Z, Wu Y, He Y, Borriss R (2012) The genome of plant growth-promoting Bacillus amyloliquefaciens subsp. plantarum strain YAU B9601-Y2 contains a gene cluster for mersacidin synthesis. J Bacteriol 194:3264–3265
He H, Williamson RT, Shen B, Graziani EI, Yang HY, Sakya SM, Petersen PJ, Carter GT (2002) Mannopeptimycins, novel antibacterial glycopeptides from Streptomyces hygroscopicus, LL-AC98. J Am Chem Soc 124:9729–9736
Herzner AM, Dischinger J, Szekat C, Josten M, Schmitz S, Yakéléba A, Reinartz R, Jansen A, Sahl HG, Piel J, Bierbaum G (2011) Expression of the lantibiotic mersacidin in Bacillus amyloliquefaciens FZB42. PLoS ONE 6:e22389
Hickey RM, Twomey DP, Ross RP, Hill C (2001) Exploitation of plasmid pMRC01 to direct transfer of mobilizable plasmids into commercial lactococcal starter strains. Appl Environ Microbiol 67:2853–2858
Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, Sandvik E, Hubbard JM, Kaniga K, Schmidt DE Jr, Gao Q, Cass RT, Karr DE, Benton BM, Humphrey PP (2005) Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49:1127–1134
Holo H, Jeknic Z, Daeschel M, Stevanovic S, Nes IF (2001) Plantaricin W from Lactobacillus plantarum belongs to a new family of two-peptide lantibiotics. Microbiology 147:643–651
Holtsmark I, Mantzilas D, Eijsink VGH, Brurberg MB (2006) Purification, characterization, and gene sequence of michiganin A, an actagardine-like lantibiotic produced by the tomato pathogen Clavibacter michiganensis subsp. michiganensis. Appl Environ Microbiol 72:5814–5821
Houlihan AJ, Russell JB (2006) Factors affecting the activity of bovicin HC5, a bacteriocin from Streptococcus bovis HC5: release, stability and binding to target bacteria. J Appl Microbiol 100:168–174
Hsu ST, Breukink E, Bierbaum G, Sahl HG, de Kruijff B, Kaptein R, van Nuland NA, Bonvin AM (2003) NMR study of mersacidin and lipid II interaction in dodecylphosphocholine micelles. Conformational changes are a key to antimicrobial activity. J Biol Chem 278:13110–13117
Huber G, Schacht U, Weidenmüller HL, Schmidt-Thomé J, Duphorn J, Tschesche R (1965) Meonomycin, a new antibiotic. II. Characterization and chemistry. Antimicrob Agents Chemother (Bethesda) 5:737–742
Huber G (1979) Moenomycin and related phosphorus-containing antibiotics. In: Hahn FE (ed) Antibiotics V/I, mechanism of action of antibacterial agents. Springer, Berlin, pp 135–153
Huffaker TC, Robbins PW (1982) Temperature sensitive yeast mutants deficient in asparagine linked glycosylation. J Biol Chem 257:3203–3210
Islam MR, Nagao J, Zendo T, Sonomoto K (2012a) Antimicrobial mechanism of lantibiotics. Biochem Soc Trans 40:1528–1533
Islam MR, Nishie M, Nagao J, Zendo T, Keller S, Nakayama J, Kohda D, Sahl HG, Sonomoto K (2012b) Ring A of nukacin ISK-1: a lipid II-binding motif for type-A(II) lantibiotic. J Am Chem Soc 134:3687–3690
Jansen EF, Hirschmann DJ (1944) Subtilin, an antibacterial product of Bacillus subtilis: culturing conditions and properties. Arch Biochem 4:297–304
Kettenring JK, Malabarba A, Vékey K, Cavalleri B (1990) Sequence determination of actagardine, a novel lantibiotic, by homonuclear 2D NMR spectroscopy. J Antibiot (Tokyo) 43:1082–1088
Kim SJ, Singh M, Wohlrab A, Yu TY, Patti GJ, O’Connor RD, VanNieuwenhze M, Schaefer J (2013) The isotridecanyl side chain of plusbacin-A3 is essential for the transglycosylase inhibition of peptidoglycan biosynthesis. Biochemistry 52:1973–1979
King A, Phillips I, Kaniga K (2004) Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J Antimicrob Chemother 53:797–803
Kingston AW, Liao X, Helmann JD (2013) Contributions of the σW, σM and σX regulons to the lantibiotic resistome of Bacillus subtilis. Mol Microbiol 90:502–518
Kruszewska D, Sahl HG, Bierbaum G, Pag U, Hynes SO, Ljungh A (2004) Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J Antimicrob Chemother 54:648–653
Kuo SC, Lampen JO (1974) Tunicamycin, inhibitor of yeast glycoprotein synthesis. Biochem Biophys Res Commun 58:287–295
Kurz M, Guba W, Vértesy L (1998) Three-dimensional structure of moenomycin A–a potent inhibitor of penicillin-binding protein 1b. Eur J Biochem 252:500–507
Laohavaleeson S, Kuti JL, Nicolau DP (2007) Telavancin: a novel lipoglycopeptide for serious gram-positive infections. Expert Opin Investig Drugs 16:347–357
Lawton EM, Cotter PD, Hill C, Ross RP (2007a) Identification of a novel two-peptide lantibiotic, haloduracin, produced by the alkaliphile Bacillus halodurans C-125. FEMS Microbiol Lett 67:64–71
Lawton EM, Ross RP, Hill C, Cotter PD (2007b) Two-peptide lantibiotics: a medical perspective. Mini Rev Med Chem 7:1236–1247
Leadbetter MR, Adams SM, Bazzini B, Fatheree PR, Karr DE, Krause KM, Lam BM, Linsell MS, Nodwell MB, Pace JL, Quast K, Shaw JP, Soriano E, Trapp SG, Villena JD, Wu TX, Christensen BG, Judice JK (2004) Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J Antibiot (Tokyo) 57:326–336
Lehle L, Tanner W (1976) The specific site of the tunicamycin inhibition in the formation of dolichol-bound Nacetylglucosamine derivatives. FEBS Lett 71:167–170
Lehrer RI (2004) Primate defensins. Nat Rev Microbiol 2:727–738
Lindenfelser LA, Pridham TG, Kemp CE (1959) Antibiotics against plant diseases. V. Activity of cinnamycin against selected microorganisms. Antibiot Chemother 9:690–695
Lunde CS, Hartouni SR, Janc JW, Mammen M, Humphrey PP, Benton BM (2009) Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother 53:3375–3383
Maffioli SI, Potenza D, Vasile F, De Matteo M, Sosio M, Marsiglia B, Rizzo V, Scolastico C, Donadio S (2009) Structure revision of the lantibiotic 97518. J Nat Prod 72:605–607
Majer F, Schmid DG, Altena K, Bierbaum G, Kupke T (2002) The flavoprotein MrsD catalyzes the oxidative decarboxylation reaction involved in formation of the peptidoglycan biosynthesis inhibitor mersacidin. J Bacteriol 184:1234–1243
Mantovani HC, Russell JB (2003) Inhibition of Listeria monocytogenes by bovicin HC5, a bacteriocin produced by Streptococcus bovis HC5. Int J Food Microbiol 89:77–83
Mantovani HC, Russell JB (2008) Bovicin HC5, a lantibiotic produced by Streptococcus bovis HC5, catalyzes the efflux of intracellular potassium but not ATP. Antimicrob Agents Chemother 52:2247–2249
Mantovani HC, Hu H, Worobo RW, Russell JB (2002) Bovicin HC5, a bacteriocin from Streptococcus bovis HC5. Microbiology 148:3347–3352
Märki F, Hänni E, Fredenhagen A, van Oostrum J (1991) Mode of action of the lanthionine-containing peptide antibiotics duramycin, duramycin B and C and cinamycin as indirect inhibitors of phospholipase A2. Biochem Pharmacol 42:2027–2035
Martin NI, Breukink E (2007) Expanding role of lipid II as a target for lantibiotics. Future Microbiol 2:513–525
Martin NI, Sprules T, Carpenter MR, Cotter PD, Hill C, Ross RP, Vederas JC (2004) Structural characterization of lacticin 3147, a two-peptide lantibiotic with synergistic activity. Biochemistry 43:3049–3056
Martínez-Cuesta MC, Requena T, Peláez C (2006) Cell membrane damage induced by lacticin 3147 enhances aldehyde formation in Lactococcus lactis IFPL730. Int J Food Microbiol 109:198–204
Mattick AT, Hirsch A (1947) Further observations on an inhibitory substance (nisin) from lactic streptococci. Lancet 2:5–8
McAuliffe O, Ryan MP, Ross RP, Hill C, Breeuwer P, Abee T (1998) Lacticin 3147, a broad-spectrum bacteriocin which selectively dissipates the membrane potential. Appl Environ Microbiol 64:439–445
McAuliffe O, Hill C, Ross RP (1999) Inhibition of Listeria monocytogenes in cottage cheese manufactured with a lacticin 3147-producing starter culture. J Appl Microbiol 86:251–256
McAuliffe O, Hill C, Ross RP (2000) Identification and overexpression of ltnl, a novel gene which confers immunity to the two-component lantibiotic lacticin 3147. Microbiology 146:129–138
McAuliffe O, O’Keeffe T, Hill C, Ross RP (2001) Regulation of immunity to the two-component lantibiotic, lacticin 3147, by the transcriptional repressor LtnR. Mol Microbiol 39:982–993
McClerren AL, Cooper LE, Quan C, Thomas PM, Kelleher NL, van der Donk WA (2006) Discovery and in vitro biosynthesis of haloduracin, a two-component lantibiotic. Proc Natl Acad Sci USA 103:17243–17248
Meier-Dieter U, Starman R, Barr K, Mayer H, Rick PD (1990) Biosynthesis of enterobacterial common antigen in Escherichia coli. Biochemical characterization of Tn10 insertion mutants defective in enterobacterial common antigen synthesis. J Biol Chem 265:13490–13497
Meng FC, Chen KT, Huang LY, Shih HW, Chang HH, Nien FY, Liang PH, Cheng TJ, Wong CH, Cheng WC (2011) Total synthesis of polyprenyl N-glycolyl lipid II as a mycobacterial transglycosylase substrate. Org Lett 13:5306–5309
Molitor E, Kluczny C, Brötz H, Bierbaum G, Jack R, Sahl HG (1996) Effects of the lantibiotic mersacidin on the morphology of staphylococci. Zentralbl Bakteriol 284:318–328
Morgan SM, Ross RP, Beresford T, Hill C (2000) Combination of hydrostatic pressure and lacticin 3147 causes increased killing of Staphylococcus and Listeria. J Appl Microbiol 88:414–420
Münch D, Roemer T, Lee SH, Engeser M, Sahl HG, Schneider T (2012) Identification and in vitro analysis of the GatD/MurT enzyme-complex catalyzing lipid II amidation in Staphylococcus aureus. PLoS Pathog 8:e1002509
Nannini EC, Stryjewski ME, Corey GR (2010) Telavancin’s interactions with the bacterial cell membrane. Future Microbiol 5:355–358
Niu WW, Neu HC (1991) Activity of mersacidin, a novel peptide, compared with that of vancomycin, teicoplanin, and daptomycin. Antimicrob Agents Chemother 35:998–1000
O’Connor EB, O’Riordan B, Morgan SM, Whelton H, O’Mullane DM, Ross RP, Hill C (2006) A lacticin 3147 enriched food ingredient reduces Streptococcus mutans isolated from the human oral cavity in saliva. J Appl Microbiol 100:1251–1260
Ökesli A, Cooper LE, Fogle EJ, van der Donk WA (2011) Nine post-translational modifications during the biosynthesis of cinnamycin. J Am Chem Soc 133:13753–13760
Okuda K, Zendo T, Sugimoto S, Iwase T, Tajima A, Yamada S, Sonomoto K, Mizunoe Y (2013) Effects of bacteriocins on methicillin-resistant Staphylococcus aureus biofilm. Antimicrob Agents Chemother 57:5572–5579
Oman TJ, van der Donk WA (2009) Insights into the mode of action of the two-peptide lantibiotic haloduracin. ACS Chem Biol 4:865–874
Oman TJ, Lupoli TJ, Wang TS, Kahne D, Walker S, van der Donk WA (2011) Haloduracin α binds the peptidoglycan precursor lipid II with 2:1 stoichiometry. J Am Chem Soc 133:17544–17547
Ostash B, Walker S (2010) Moenomycin family antibiotics: chemical synthesis, biosynthesis, biological activity. Nat Prod Rep 27:1594–1617
O’Sullivan L, Morgan SM, Ross RP, Hill C (2002) Elevated enzyme release from lactococcal starter cultures on exposure to the lantibiotic lacticin 481, produced by Lactococcus lactis DPC5552. J Dairy Sci 85:2130–2140
Pace JL, Judice JK (2005) Telavancin (Theravance). Curr Opin Investig Drugs 6:216–225
Pace JL, Yang G (2006) Glycopeptides: Update on an old successful antibiotic class. Biochem Pharmacol 71:968–980
Paiva AD, Breukink E, Mantovani HC (2011) Role of lipid II and membrane thickness in the mechanism of action of the lantibiotic bovicin HC5. Antimicrob Agents Chemother 55:5284–5293
Paiva AD, Irving N, Breukink E, Mantovani HC (2012a) Interaction with lipid II induces conformational changes in bovicin HC5 structure. Antimicrob Agents Chemother 56:4586–4593
Paiva AD, de Oliveira MD, de Paula SO, Baracat-Pereira MC, Breukink E, Mantovani HC (2012b) Toxicity of bovicin HC5 against mammalian cell lines and the role of cholesterol in bacteriocin activity. Microbiology 158:2851–2858
Paiva AD, Fernandes KM, Dias RS, Dos Santos Rocha A, Licursi de Oliveira L, Neves CA, Oliveira de Paula S, Mantovani HC (2013) Safety evaluation of the antimicrobial peptide bovicin HC5 orally administered to a murine model. BMC Microbiol 13:69
Ramare F, Nicoli J, Dabard J, Corring T, Ladire M, Gueugneau AM, Raibaud P (1993) Trypsin-dependent production of an antibacterial substance by a human Peptostreptococcus strain in gnotobiotic rats and in vitro. Appl Environ Microbiol 59:2876–2883
Rea MC, Cogan TM (1994) Buttermilk plants: the Irish version of kefir. Ir Scientist 2:7
Rea MC, Clayton E, O’Connor PM, Shanahan F, Kiely B, Ross RP, Hill C (2007) Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains. J Med Microbiol 56:940–946
Rea MC, Dobson A, O’Sullivan O, Crispie F, Fouhy F, Cotter PD, Shanahan F, Kiely B, Hill C, Ross RP (2011) Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci USA 108:4639–4644
Rogers LA, Whittier EO (1928) Limiting factors in the lactic fermentation. J Bacteriol 16:211–229
Ruzin A, Singh G, Severin A, Yang Y, Dushin RG, Sutherland AG, Minnick A, Greenstein M, May MK, Shlaes DM, Bradford PA (2004) Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant gram-positive bacteria. Antimicrob Agents Chemother 48:728–738
Ryan MP, Rea MC, Hill C, Ross RP (1996) An Application in cheddar cheese manufacture for a strain of Lactococcus lactis producing a novel broad-spectrum bacteriocin, lacticin 3147. Appl Environ Microbiol 62:612–619
Ryan MP, Meaney WJ, Ross RP, Hill C (1998) Evaluation of lacticin 3147 and a teat seal containing this bacteriocin for inhibition of mastitis pathogens. Appl Environ Microbiol 64:2287–2290
Ryan MP, Flynn J, Hill C, Ross RP, Meaney WJ (1999a) The natural food grade inhibitor, lacticin 3147, reduced the incidence of mastitis after experimental challenge with Streptococcus dysgalactiae in nonlactating dairy cows. J Dairy Sci 82:2625–2631
Ryan MP, Jack RW, Josten M, Sahl HG, Jung G, Ross RP, Hill C (1999b) Extensive post-translational modification, including serine to d-alanine conversion, in the two-component lantibiotic, lacticin 3147. J Biol Chem 274:37544–37550
Sahl HG (1991) Pore formation in bacterial membranes by cationic lantibiotics. In: Jung G, Sahl HG (eds) Nisin and novel lantibiotics. Escom, Leiden, pp 347–358
Sánchez A, Villanueva JR, Villa TG (1982) Effect of tunicamycin on exo- 1,3-β-d-glucanase synthesis and secretion by cells and protoplasts of Sacchavomyces cevevisiae. J Gen Microbiol 128:3051–3060
Sashihara T, Kimura H, Higuchi T, Adachi A, Matsusaki H, Sonomoto K, Ishizaki A (2000) A novel lantibiotic, nukacin ISK-1, of Staphylococcus warneri ISK-1: cloning of the structural gene and identification of the structure. Biosci Biotechnol Biochem 64:2420–2428
Sashihara T, Dan M, Kimura H, Matsusaki H, Sonomoto K, Ishizaki A (2001) The effect of osmotic stress on the production of nukacin ISK-1 from Staphylococcus warneri ISK-1. Appl Microbiol Biotechnol 56:496–501
Sass V, Schneider T, Wilmes M, Körner C, Tossi A, Novikova N, Shamova O, Sahl HG (2010) Human beta-defensin 3 inhibits cell wall biosynthesis in Staphylococci. Infect Immun 78:2793–2800
Schmitt P, Wilmes M, Pugnière M, Aumelas A, Bachère E, Sahl HG, Schneider T, Destoumieux-Garzón D (2010) Insight into invertebrate defensin mechanism of action: oyster defensins inhibit peptidoglycan biosynthesis by binding to lipid II. J Biol Chem 285:29208–29216
Schmitz S, Hoffmann A, Szekat C, Rudd B, Bierbaum G (2006) The lantibiotic mersacidin is an autoinducing peptide. Appl Environ Microbiol 72:7270–7277
Schneider T, Sahl HG (2010a) An oldie but a goodie—cell wall biosynthesis as antibiotic target pathway. Int J Med Microbiol 300:161–169
Schneider T, Sahl HG (2010b) Lipid II and other bactoprenol-bound cell wall precursors as drug targets. Curr Opin Investig Drugs 11:157–164
Schneider TR, Kärcher J, Pohl E, Lubini P, Sheldrick GM (2000) Ab initio structure determination of the lantibiotic mersacidin. Acta Cryst. D56:705–713
Schneider T, Senn MM, Berger-Bächi B, Tossi A, Sahl HG, Wiedemann I (2004) In vitro assembly of a complete, pentaglycine interpeptide bridge containing cell wall precursor (lipid II-Gly5) of Staphylococcus aureus. Mol Microbiol 53:675–685
Schneider T, Kruse T, Wimmer R, Wiedemann I, Sass V, Pag U, Jansen A, Nielsen AK, Mygind PH, Raventós DS, Neve S, Ravn B, Bonvin AM, De Maria L, Andersen AS, Gammelgaard LK, Sahl HG, Kristensen HH (2010) Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. Science 328:1168–1172
Selsted ME, Ouellette AJ (2005) Mammalian defensins in the antimicrobial immune response. Nat Immunol 6:551–557
Sherwood EJ, Bibb MJ (2013) The antibiotic planosporicin coordinates its own production in the actinomycete Planomonospora alba. Proc Natl Acad Sci USA 110:2500–2509
Sherwood EJ, Hesketh AR, Bibb MJ (2013) Cloning and analysis of the planosporicin lantibiotic biosynthetic gene cluster of Planomonospora alba. J Bacteriol 195:2309–2321
Shi Y, Bueno A, van der Donk WA (2012) Heterologous production of the lantibiotic Ala(0)actagardine in Escherichia coli. Chem Commun (Camb) 48:10966–10968
Silkin L, Hamza S, Kaufman S, Cobb SL, Vederas JC (2008) Spermicidal bacteriocins: lacticin 3147 and subtilosin A. Bioorg Med Chem Lett 18:3103–3106
Singh MP, Petersen PJ, Weiss WJ, Janso JE, Luckman SW, Lenoy EB, Bradford PA, Testa RT, Greenstein M (2003) Mannopeptimycins, new cyclic glycopeptide antibiotics produced by Streptomyces hygroscopicus LL-AC98: antibacterial and mechanistic activities. Antimicrob Agents Chemother 47:62–69
Sinko W, Wang Y, Zhu W, Zhang Y, Feixas F, Cox CL, Mitchell DA, Oldfield E, McCammon JA (2014) Undecaprenyl diphosphate synthase inhibitors: antibacterial drug leads. J Med Chem 57:5693–5701
Somma S, Merati W, Parenti F (1977) Gardimycin, a new antibiotic inhibiting peptidoglycan synthesis. Antimicrob Agents Chemother 11:396–401
Subramaniam-Niehaus B, Schneider T, Metzger JW, Wohlleben W (1997) Isolation and analysis of moenomycin and its biosynthetic intermediates from Streptomyces ghanaensis (ATCC 14672) wildtype and selected mutants. Z Naturforsch C 52:217–226
Suda S, Westerbeek A, O’Connor PM, Ross RP, Hill C, Cotter PD (2010) Effect of bioengineering lacticin 3147 lanthionine bridges on specific activity and resistance to heat and proteases. Chem Biol 17:1151–1160
Szekat C, Jack RW, Skutlarek D, Färber H, Bierbaum G (2003) Construction of an expression system for site-directed mutagenesis of the lantibiotic mersacidin. Appl Environ Microbiol 69:3777–3783
Touzé T, Barreteau H, El Ghachi M, Bouhss A, Barnéoud-Arnoulet A, Patin D, Sacco E, Blanot D, Arthur M, Duché D, Lloubès R, Mengin-Lecreulx D (2012) Colicin M, a peptidoglycan lipid-II-degrading enzyme: potential use for antibacterial means? Biochem Soc Trans 40:1522–1527
Turner DL, Brennan L, Meyer HE, Lohaus C, Siethoff C, Costa HS, Gonzalez B, Santos H, Suárez JE (1999) Solution structure of plantaricin C, a novel lantibiotic. Eur J Biochem 264:833–839
Twomey DP, Wheelock AI, Flynn J, Meaney WJ, Hill C, Ross RP (2000) Protection against Staphylococcus aureus mastitis in dairy cows using a bismuth-based teat seal containing the bacteriocin, lacticin 3147. J Dairy Sci 3:1981–1988
van Bambeke F (2006) Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy. Curr Opin Investig Drugs 7:740–749
van Wageningen AM, Kirkpatrick PN, Williams DH, Harris BR, Kershaw JK, Lennard NJ, Jones M, Jones SJ, Solenberg PJ (1998) Sequencing and analysis of genes involved in the biosynthesis of a vancomycin group antibiotic. Chem Biol 5:155–162
Varney KM, Bonvin AM, Pazgier M, Malin J, Yu W, Ateh E, Oashi T, Lu W, Huang J, Diepeveen-de Buin M, Bryant J, Breukink E, Mackerell AD Jr, de Leeuw EP (2013) Turning defense into offense: defensin mimetics as novel antibiotics targeting lipid II. PLoS Pathog 9:e1003732
Vértesy L, Aretz W, Bonnefoy A, Ehlers E, Kurz M, Markus A, Schiell M, Vogel M, Wink J, Kogler H (1999) Ala(0)-actagardine, a new lantibiotic from cultures of Actinoplanes liguriae ATCC 31048. J Antibiot (Tokyo) 52:730–741
Volke F, Waschipky R, Pampel A, Donnerstag A, Lantzsch G, Pfeiffer H, Richter W, Klose G, Welzel P (1997) Characterisation of antibiotic moenomycin A interaction with phospholipid model membranes. Chem Phys Lipids 85:115–123
Vollmer J, Schiefer A, Schneider T, Jülicher K, Johnston KL, Taylor MJ, Sahl HG, Hoerauf A, Pfarr K (2013) Requirement of lipid II biosynthesis for cell division in cell wall-less Wolbachia, endobacteria of arthropods and filarial nematodes. Int J Med Microbiol 303:140–149
Wakamiya T, Ueki Y, Shiba T, Kido Y, Motoki Y (1985) The structure of ancovenin, a new peptide inhibitor of angiotensin I converting enzyme. Tetrahedron Lett 26:665–668
Wallhausser KH, Nesemann G, Prave P, Steigler A (1965) Moenomycin, a new antibiotic. Fermentation and isolationI. Antimicrob Agents Chemother (Bethesda) 5:734–736
Whitford MF, McPherson MA, Forster RJ, Teather RM (2001) Identification of bacteriocin-like inhibitors from rumen Streptococcus spp. and isolation and characterization of bovicin 255. Appl Environ Microbiol 67:569–574
Widdick DA, Dodd HM, Barraille P, White J, Stein TH, Chater KF, Gasson MJ, Bibb MJ (2003) Cloning and engineering of the cinnamycin biosynthetic gene cluster from Streptomyces cinnamoneus cinnamoneus DSM 40005. Proc Natl Acad Sci USA 100:4316–4321
Wiedemann I, Böttiger T, Bonelli RR, Wiese A, Hagge SO, Gutsmann T, Seydel U, Deegan L, Hill C, Ross P, Sahl HG (2006a) The mode of action of the lantibiotic lacticin 3147 a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. Mol Microbiol 61:285–296
Wiedemann I, Böttiger T, Bonelli RR, Schneider T, Sahl HG, Martínez B (2006b) Lipid II-Based Antimicrobial Activity of the Lantibiotic Plantaricin C. Appl Environ Microbiol 72:2809–2814
Wilson-Stanford S, Kalli A, Håkansson K, Kastrantas J, Orugunty RS, Smith L (2009) Oxidation of lanthionines renders the lantibiotic nisin inactive. Appl Environ Microbiol 75:1381–1387
**ao H, Chen X, Chen M, Tang S, Zhao X, Huan L (2004) Bovicin HJ50, a novel lantibiotic produced by Streptococcus bovis HJ50. Microbiology 150:103–108
Zimmermann N, Metzger JW, Jung G (1995) The tetracyclic lantibiotic actagardine. 1H-NMR and 13C-NMR assignments and revised primary structure. Eur J Biochem 228:786–797
Zipser RD, Laffi G (1985) Prostaglandins, thromboxanes and leukotrienes in clinical medicine. West J Med 143:485–497
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Villa, T.G., Feijoo-Siota, L., Rama, J.L.R., Sánchez-Pérez, A., de Miguel-Bouzas, T. (2016). The Case of Lipid II: The Achilles’ Heel of Bacteria. In: Villa, T., Vinas, M. (eds) New Weapons to Control Bacterial Growth. Springer, Cham. https://doi.org/10.1007/978-3-319-28368-5_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-28368-5_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-28366-1
Online ISBN: 978-3-319-28368-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)